Ibrutinib EU Indications Expanded in CLL and Waldenstrom Macroglobulinemia

Aug 13, 2019 – The European Commission has expanded the approval of ibrutinib to include use in combination with obinutuzumab for adult patients with previously untreated chronic lymphocytic leukemia (CLL), and also in combination with rituximab for the treatment of adult patients with Waldenström macroglobulinemia (WM). The expanded indications stem from a positive recommendation from the European Medicines Agency’s Committee for Medicinal … (leggi tutto)